Arrowhead falls 15% the day its closest rival halves a sales forecast
Why is Arrowhead stock down today?
Arrowhead closed down 15.3% on the day Ionis, which sells the closest competing drug, halved its 2026 sales forecast for it, citing a slower launch in patients with severe hypertriglyceridemia (very high blood fats), the market Arrowhead hopes to enter. Neither Arrowhead nor the sources we reviewed established why its shares fell. Arrowhead's weekend data, 78% fewer pancreatitis attacks and a blood-sugar imbalance, repeated results it first published in July and August.
What it means
- What changed
- Ionis cut its 2026 TRYNGOLZA forecast by about half after a slower sHTG launch; the forecast covers all the drug's sales, including FCS.
- What hasn't changed
- Plozasiran's Phase 3 results, Arrowhead's plan to file for sHTG by year-end, and the FDA's six-month review pilot it was admitted to in October.
- Next · Nov 12, 2026, 4:30 p.m. ET
- Arrowhead's fiscal 2026 results and call, with Redemplo sales and an update on the sHTG filing.
- Move
- ▼ 15.3%
- Price
- $58.16 → $49.24
- Value lost
- ~$1.3B
- Pancreatitis attacks vs placebo
- 78% fewer (pooled)
- TRYNGOLZA 2026 sales forecast
- ~$50M, was $100–110M
- Worsening blood-sugar control
- 14.3% vs 8.7% placebo
Prices: Yahoo Finance and CNBC (Nasdaq close), Nov 9, 2026 · Company data: 10-Q, Jun 30, 2026 · What these numbers mean
Closing prices: $49.24 on Nov 9, 2026, against $58.16 on Nov 6 (Yahoo Finance and CNBC). Value lost is our estimate, using the 141,254,467 common shares outstanding on Jul 30, 2026, on the cover of its latest 10-Q. Ionis, XBI and index changes are Nov 9 closes against Nov 6 (CNBC).
Snapshot at the Nov 9, 2026 close
- Market value
- $7.0B
- Enterprise value
- $6.2B†
- Price/sales
- 10.4×
- EV/sales
- 9.3×
- P/E
- n/m
- Price/FCF
- n/m
- Revenue growth
- +17%
- FCF margin
- −11%
- Net cash
- $735M†
Our calculation from the company's filings (latest: 10-Q for the quarter to Jun 30, 2026, filed Aug 4, 2026); not investment advice. Revenue, earnings and cash flow: 12 months to Jun 30, 2026. Price $49.24 (Yahoo Finance and CNBC (Nasdaq close)); 141.3 million shares (common shares on the cover page of the 10-Q filed Aug 4, 2026). n/m = not meaningful (e.g. negative earnings). † Debt excludes the $392.5M Royalty Pharma liability, which is not repayable in cash.
Price data
| Date | Close |
|---|---|
| Oct 12, 2026 | $60.73 |
| Oct 13, 2026 | $58.13 |
| Oct 14, 2026 | $58.37 |
| Oct 15, 2026 | $58.50 |
| Oct 16, 2026 | $55.90 |
| Oct 19, 2026 | $57.23 |
| Oct 20, 2026 | $58.92 |
| Oct 21, 2026 | $58.84 |
| Oct 22, 2026 | $58.36 |
| Oct 23, 2026 | $58.02 |
| Oct 26, 2026 | $58.98 |
| Oct 27, 2026 | $59.03 |
| Oct 28, 2026 | $60.21 |
| Oct 29, 2026 | $60.49 |
| Oct 30, 2026 | $59.90 |
| Nov 2, 2026 | $59.57 |
| Nov 3, 2026 | $59.53 |
| Nov 4, 2026 | $61.65 |
| Nov 5, 2026 | $57.46 |
| Nov 6, 2026 | $58.16 |
| Nov 9, 2026 | $49.24 |
What happened
Arrowhead develops RNA-interference medicines, drugs that switch off the gene behind a disease. Its one own product, Redemplo (plozasiran), is approved in the US for familial chylomicronemia syndrome (FCS), a rare disease of extremely high blood fats, and Arrowhead plans to ask the FDA by the end of 2026 to extend it to severe hypertriglyceridemia (sHTG), a far larger group of patients (our Long View on Arrowhead).
- At the American Heart Association meeting on Saturday, Arrowhead presented a pooled analysis of its two Phase 3 trials in 757 adults with sHTG: plozasiran cut acute pancreatitis attacks by 78% against placebo, and by 91% in patients who had pancreatitis in the previous five years, the company said.
- On Monday morning Ionis, whose TRYNGOLZA (olezarsen) already treats sHTG and competes with plozasiran, lowered its 2026 sales forecast for the drug to about $50 million from $100–110 million. Its report covered the first full quarter of TRYNGOLZA’s sHTG launch, and it said the launch is ramping “more gradually than expected”; the forecast covers all the drug’s sales, including FCS. Ionis shares closed down 21.4%.
- Arrowhead’s blood-sugar figure wasn’t new. Some coverage pointed to worsening glycemic control in 14% of plozasiran patients against 8.7% on placebo. Those rates are in Arrowhead’s weekend release, but the same figures (14.3% against 8.7%) were in its Aug 30 release on the full trial results, which said average HbA1c, a measure of long-run blood sugar, showed no worsening over time. Arrowhead’s shares fell 3.0% on the first trading day after that release (Yahoo Finance closes; our calculation).
Arrowhead closed down 15.3% at $49.24, from $58.16 on Friday (Yahoo Finance and CNBC), about $1.3 billion of market value (our estimate). The SPDR S&P Biotech ETF (XBI) rose 3.1%, the S&P 500 2.3% and the Nasdaq Composite 2.7% (CNBC). Arrowhead made no statement about the fall. The shares had already slid 34% from $88.70 on Jul 22, the day of its Phase 3 headline results, to Friday’s close (Yahoo Finance; our calculation).
Change on Nov 9, 2026, from the Nov 6 close (%)
Arrowhead and Ionis both fell sharply on a day biotech stocks rose.
Show the data table
| Stock | Change (%) |
|---|---|
| Ionis (IONS) | −21.4 |
| Arrowhead (ARWR) | −15.3 |
| SPDR S&P Biotech ETF (XBI) | 3.1 |
Why the market reacted this way
The company releases don’t establish what drove the selling. Coverage offered two possible explanations.
- Ionis’s revision raises a launch-speed question for Arrowhead. TRYNGOLZA is already sold to the sHTG patients plozasiran hopes to reach, and Ionis said its first full quarter there showed a more gradual ramp than it had anticipated. IBTimes wrote that investors appeared concerned weaker demand for Ionis’s drug could signal a slower rollout for Redemplo, but said no direct link to Arrowhead’s fall had been confirmed. It added that Arrowhead’s case rests partly on dosing every three months against TRYNGOLZA’s monthly schedule.
- OptionsPilot suggested that investors focused on the blood-sugar figures. Those had already appeared in Arrowhead’s August release, when the shares fell 3.0%.
- Arrowhead’s own sales are still small. Redemplo sales were about $2.4 million in the June quarter (our calculation: total revenue less collaboration revenue in Arrowhead’s Aug 4 10-Q), and sHTG, where Ionis has just halved its forecast, covers far more patients than FCS.
Does this change Arrowhead’s future?
What did NOT change
The Phase 3 results are the same ones Arrowhead reported in July and August. Arrowhead said on Oct 7 that the FDA admitted its planned sHTG application to the Split Real Time Application Review (STAR) pilot, qualifying it for a six-month priority-review goal, and it says it will file by the end of 2026. On Nov 2 it also replaced its Sixth Street loan, on which 15% a year was added to the debt, with a new $400 million loan whose interest is paid in cash at a floating rate, its 8-K shows.
What DID change
Ionis’s revision, after the first full quarter of its sHTG launch, suggests uptake in that market may be slower than Ionis planned, at least in the first year. It doesn’t separate sHTG demand from FCS sales.
Our read
Our interpretation is that the fall says more about how quickly the sHTG market will grow than about plozasiran’s results, which didn’t change. Arrowhead’s fiscal results on Nov 12 should show the latest Redemplo sales in FCS, though not yet any in sHTG.
The other view
Ionis, the company that cut its forecast, says the slower ramp reflects the early work of establishing a new treatment and that it remains confident in TRYNGOLZA's "multi-billion-dollar peak sales"; it kept its total-revenue forecast unchanged.
Source: Ionis: third-quarter 2026 results (SEC 8-K, Exhibit 99.1), Nov 9
What to watch next
- Nov 12, 2026, 4:30 p.m. ET
- Arrowhead's results for the fiscal year to Sep 30, including Redemplo sales in the September quarter.
- By the end of 2026 (company plan)
- Arrowhead's supplemental FDA application to extend plozasiran to severe hypertriglyceridemia, under the STAR pilot with a six-month priority-review goal.
- Early 2027 (expected)
- Ionis's fourth-quarter TRYNGOLZA sales, the next read on how fast the sHTG market is building.
Quick questions
What is the difference between FCS and severe hypertriglyceridemia?
Both mean very high blood triglycerides, a type of fat, which can cause attacks of acute pancreatitis. Familial chylomicronemia syndrome (FCS) is a rare genetic form, and it is where Redemplo is approved. Severe hypertriglyceridemia (sHTG) is a much larger group of patients, where Ionis's TRYNGOLZA is already sold and Arrowhead plans to file for approval by the end of 2026.
Was the blood-sugar finding new?
No. Arrowhead's Aug 30 release on the full Phase 3 results reported worsening glycemic control in 14.3% of plozasiran patients and 8.7% on placebo, and said average HbA1c, a measure of long-run blood sugar, showed minimal to modest change with no worsening over time. The Nov 7 release repeated the rates for the pooled safety population.
When does Arrowhead next report results?
Arrowhead says it will hold its fiscal 2026 results webcast and call on Nov 12 at 4:30 p.m. ET, covering the year to Sep 30, 2026.
About Arrowhead: Website (external site)Investor relations (external site)SEC filings (external site)Wikipedia (external site)
+ 8 more
Accessed Nov 9, 2026: Arrowhead: webcast of 2026 fiscal year-end results (Business Wire via BioSpace), Nov 3 · Arrowhead: refinancing of its term loan (SEC 8-K), Nov 4 · Arrowhead: entry into the FDA STAR pilot for plozasiran in sHTG (Business Wire), Oct 7 · IBTimes: Arrowhead stock tumbles 15% on same day rival Ionis cuts Tryngolza forecast, Nov 9 · OptionsPilot: Arrowhead drops 17% as a rival's weak launch and blood-sugar data hit the same day, Nov 9 · HCPLive: SHASTA-3/4 pooled analysis at AHA 2026, Nov 8 · Arrowhead: Form 10-Q for the quarter to Jun 30, 2026 (revenue, cover shares), Aug 4 · Yahoo Finance: ARWR price history
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.